Ameritas Advisory Services LLC Has $5.11 Million Stake in Amgen Inc. $AMGN

Key Points

• Ameritas Advisory Services increased its Amgen position by 139.3% in the second quarter, holding 14,119 shares worth approximately $5.11 million. Institutional investors collectively own 76.5% of Amgen’s stock.
• Amgen exceeded quarterly expectations with $6.29 adjusted EPS and $10.05 billion in revenue, up 9.5% year over year. The company also declared a quarterly dividend of $2.52, equivalent to a 2.3% annualized yield.
• Pipeline concerns weigh on the outlook: Novartis’s failed pelacarsen cardiovascular trial raised doubts about the broader lipoprotein(a) treatment approach and Amgen’s olpasiran trial. Analysts maintain a consensus “Hold” rating, while two senior vice presidents sold shares during the quarter.

Ameritas Advisory Services LLC boosted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 139.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,119 shares of the medical research company's stock after buying an additional 8,220 shares during the quarter. Ameritas Advisory Services LLC's holdings in Amgen were worth $5,113,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Tower View Wealth Management LLC grew its stake in shares of Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after purchasing an additional 63 shares during the period. Manning & Napier Advisors LLC raised its holdings in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after buying an additional 32 shares in the last quarter. Evergreen Advisors LLC bought a new position in shares of Amgen during the 1st quarter worth approximately $37,000. Sfam LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $38,000. Finally, Advocate Investing Services LLC acquired a new stake in Amgen in the 4th quarter valued at $39,000. Institutional investors own 76.50% of the company's stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen continues to be viewed as a long-term growth candidate, supported by its diversified drug portfolio and potential pipeline contributions. However, the bullish commentary is largely based on broad fundamental and valuation screens rather than a new company-specific announcement. Why Amgen Is a Top Growth Stock for the Long-Term
• Neutral Sentiment: An industry report identified Amgen, Roche and Johnson & Johnson as leading participants in the expanding oncology bi/multispecific-drug market. The report offers sector context but does not announce a new Amgen asset, deal or clinical result, so its immediate effect on AMGN is likely limited. Bi/Multispecific Oncology Market Report
• Neutral Sentiment: Congressman David Taylor disclosed several trades, including sales of biotech holdings. These transactions are not directly linked to Amgen’s operations or outlook and do not provide a meaningful fundamental signal for AMGN. Congressional Stock Trades
• Negative Sentiment: Novartis reported that its Phase III pelacarsen study failed to reduce cardiovascular events, despite testing a lower target biomarker level. Investors are concerned that the result may challenge the broader “lipoprotein(a)” treatment mechanism and make it harder for Amgen’s 7,297-patient olpasiran outcome trial to produce a positive result. Amgen Shares Fall as Pelacarsen Misses Phase III Goal
• Negative Sentiment: The pelacarsen failure prompted a pullback in Amgen shares as investors reassessed olpasiran’s probability of success and potential commercial value. The concern is currently a pipeline-risk repricing, not evidence that Amgen’s approved products or recent earnings performance have deteriorated. Amgen’s 7,297-Patient Heart Bet Inherited a Higher Bar

Insider Transactions at Amgen

In other news, SVP Nancy Grygiel sold 2,970 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company's stock.

Amgen Price Performance

AMGN stock opened at $437.23 on Tuesday. The stock has a 50-day moving average price of $398.92 and a two-hundred day moving average price of $367.59. The stock has a market cap of $236.38 billion, a PE ratio of 27.17, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the previous year, the business earned $6.02 EPS. Amgen's revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts forecast that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen's dividend payout ratio (DPR) is 62.65%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on AMGN shares. Mizuho increased their price target on Amgen from $303.00 to $352.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 18th. Daiwa Securities Group cut their price objective on Amgen from $410.00 to $390.00 and set an "outperform" rating for the company in a research report on Wednesday, May 13th. Truist Financial boosted their price objective on Amgen from $340.00 to $362.00 and gave the stock a "hold" rating in a research note on Wednesday, August 5th. Scotiabank increased their target price on Amgen from $385.00 to $450.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Finally, TD Cowen lifted their price target on Amgen from $420.00 to $452.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $381.68.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.